{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:35:10Z","timestamp":1774366510007,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"19-20","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00508-019-01539-2","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T11:30:59Z","timestamp":1567164659000},"page":"493-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association of sprue-like enteropathy and angiotensin receptor-1 antagonists"],"prefix":"10.1007","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-6076","authenticated-orcid":false,"given":"Ren\u00e9 R.","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Datz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"1539_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.12691\/ijcd-2-2-5","volume":"2","author":"HJ Freeman","year":"2014","unstructured":"Freeman\u00a0HJ. Drug-induced Sprue-like intestinal disease. Int J Celiac Dis. 2014;2:49\u201353.","journal-title":"Int J Celiac Dis"},{"key":"1539_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.14797\/mdcj-12-4-230","volume":"12","author":"A Adike","year":"2016","unstructured":"Adike\u00a0A, Corral\u00a0J, Rybnicek\u00a0D, Sussman\u00a0D, Shah\u00a0S, Quigley\u00a0E. Olmesartan-induced Enteropathy. Methodist Debakey Cardiovasc\u00a0J. 2016;12:230\u20132.","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"1539_CR3","doi-asserted-by":"publisher","first-page":"e0125024","DOI":"10.1371\/journal.pone.0125024","volume":"10","author":"S Scialom","year":"2015","unstructured":"Scialom\u00a0S, Malamut\u00a0G, Meresse\u00a0B, et\u00a0al. Gastrointestinal disorder associated with Olmesartan mimics Autoimmune Enteropathy. PLoS ONE. 2015;10:e125024.","journal-title":"PLoS ONE"},{"key":"1539_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.12780","volume":"40","author":"G Ianiro","year":"2014","unstructured":"Ianiro\u00a0G, Bibbo\u00a0S, Montalto\u00a0M, Ricci\u00a0R, Gasbarrini\u00a0A, Cammarota\u00a0G. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40:16\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"1539_CR5","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.mayocp.2012.06.003","volume":"87","author":"A Rubio-Tapia","year":"2012","unstructured":"Rubio-Tapia\u00a0A, Herman\u00a0ML, Ludvigsson\u00a0JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87:732\u20138.","journal-title":"Mayo Clin Proc"},{"key":"1539_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4321\/S1130-01082014000200011","volume":"106","author":"G Fiorucci","year":"2014","unstructured":"Fiorucci\u00a0G, Puxeddu\u00a0E, Colella\u00a0R, Reboldi\u00a0PG, Villanacci\u00a0V, Bassotti\u00a0G. Severe spruelike enteropathy due to olmesartan. Rev Esp Enferm Dig. 2014;106:142\u20134.","journal-title":"Rev Esp Enferm Dig"},{"key":"1539_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/ajg.2013.45","volume":"108","author":"M DeGaetani","year":"2013","unstructured":"DeGaetani\u00a0M, Tennyson\u00a0CA, Lebwohl\u00a0B, et\u00a0al. Villous atrophy and negative celiac serology: a\u00a0diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108:647\u201353.","journal-title":"Am J Gastroenterol"},{"key":"1539_CR8","first-page":"1","volume":"2013","author":"SE Dreifuss","year":"2013","unstructured":"Dreifuss\u00a0SE, Tomizawa\u00a0Y, Farber\u00a0NJ, Davison\u00a0JM, Sohnen\u00a0AE. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Rep Gastrointest Med. 2013;2013:1\u20133.","journal-title":"Case Rep Gastrointest Med"},{"key":"1539_CR9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s00508-015-0882-8","volume":"127","author":"E Fabian","year":"2015","unstructured":"Fabian\u00a0E, Schiller\u00a0D, Wenzl\u00a0H, et al. Clinical-Pathological Conference Series from the Medical University of Graz: Case No 156: 82-year-old woman with chronic diarrhea and weight loss of 20 kilograms. Wien Klin Wochenschr. 2015;127:974\u201380.","journal-title":"Wien Klin Wochenschr"},{"key":"1539_CR10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/gutjnl-2015-309690","volume":"65","author":"M Basson","year":"2016","unstructured":"Basson\u00a0M, Mezzarobba\u00a0M, Weill\u00a0A, et\u00a0al. Severe intestinal malabsorption associated with olmesartan: a\u00a0French nationwide observational cohort study. Gut. 2016;65:1664\u20139.","journal-title":"Gut"},{"key":"1539_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/apt.12937","volume":"40","author":"L Marthey","year":"2014","unstructured":"Marthey\u00a0L, Cadiot\u00a0G, Seksik\u00a0P, et al. Olmesartan-associated enteropathy: results of a\u00a0national survey. Aliment Pharmacol Ther. 2014;40:1103\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1539_CR12","first-page":"62","volume":"30","author":"L Mondet","year":"2016","unstructured":"Mondet\u00a0L, Pierson-Marchandise\u00a0M, Gras\u00a0V, et al. Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! A case report with candesartan. Fundam Clin Pharmacol. 2016;30:62.","journal-title":"Fundam. Clin. Pharmacol."},{"key":"1539_CR13","first-page":"87","volume":"51","author":"H Maier","year":"2015","unstructured":"Maier\u00a0H, Hehemann\u00a0K, Vieth\u00a0M. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan. Cesk Patol. 2015;51:87\u20138.","journal-title":"Cesk Patol"},{"key":"1539_CR14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/apt.12870","volume":"40","author":"G Cammarota","year":"2014","unstructured":"Cammarota\u00a0G, Ianiro\u00a0G, Bibbo\u00a0S, Letter\u00a0GA. telmisartan associated enteropathy\u2014is there any class effect? Authors\u2019 reply. Aliment Pharmacol Ther. 2014;40:570.","journal-title":"Aliment Pharmacol Ther"},{"key":"1539_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/MCG.0000000000000383","volume":"49","author":"A Negro","year":"2015","unstructured":"Negro\u00a0A, Rossi\u00a0GM, Santi\u00a0R, Iori\u00a0V, De Marco\u00a0L. A case of severe Sprue-like Enteropathy associated with Losartan. J\u00a0Clin Gastroenterol. 2015;49:794.","journal-title":"J Clin Gastroenterol"},{"key":"1539_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.14309\/crj.2015.15","volume":"2","author":"ML Herman","year":"2015","unstructured":"Herman\u00a0ML, Rubio-Tapia\u00a0A, Wu\u00a0TT, Murray\u00a0JA. A case of severe Sprue-like Enteropathy associated with Valsartan. Acg Case Rep\u00a0J. 2015;2:92\u20134.","journal-title":"Acg Case Rep J"},{"key":"1539_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1569-1993(17)30627-6","volume":"16","author":"AP Sawant","year":"2017","unstructured":"Sawant\u00a0AP, Spoletini\u00a0G, Etherington\u00a0C. Losartan-associated spruelike enteropathy in a\u00a0post-lung transplant cystic fibrosis patient. J\u00a0Cyst Fibros. 2017;16:135.","journal-title":"J Cyst Fibros"},{"key":"1539_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/apt.12850","volume":"40","author":"J Cyrany","year":"2014","unstructured":"Cyrany\u00a0J, Vasatko\u00a0T, Machac\u00a0J, Nova\u00a0M, Szanyi\u00a0J, Kopacova\u00a0M. Letter: telmisartan-associated enteropathy\u2014is there any class effect? Aliment Pharmacol Ther. 2014;40:569\u201370.","journal-title":"Aliment Pharmacol Ther"},{"key":"1539_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.5217\/ir.2017.15.3.419","volume":"15","author":"HS Mandavdhare","year":"2017","unstructured":"Mandavdhare\u00a0HS, Sharma\u00a0V, Prasad\u00a0KK, Kumar\u00a0A, Rathi\u00a0M, Rana\u00a0SS. Telmisartan-induced sprue-like enteropathy: a\u00a0case report and a\u00a0review of patients using non-olmesartan angiotensin receptor blockers. Intest Res. 2017;15:419\u201321.","journal-title":"Intest Res"},{"key":"1539_CR20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/14740338.2017.1376647","volume":"16","author":"N De Bortoli","year":"2017","unstructured":"De Bortoli\u00a0N, Ripellino\u00a0C, Cataldo\u00a0N, Marchi\u00a0S. Unspecified intestinal malabsorption in patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a\u00a0retrospective analysis in primary care settings. Expert Opin Drug Saf. 2017;16:1221\u20135. \n                    https:\/\/doi.org\/10.1080\/14740338.2017.1376647\n                    \n                  .","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1539_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/pds.4402","volume":"27","author":"P Malfertheiner","year":"2018","unstructured":"Malfertheiner\u00a0P, Ripellino\u00a0C, Cataldo\u00a0N. Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy. Pharmacoepidemiol Drug Saf. 2018;27(6):581\u2013586. \n                    https:\/\/doi.org\/10.1002\/pds.4402","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1539_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3904\/kjim.2017.002","volume":"34","author":"SC You","year":"2019","unstructured":"You\u00a0SC, Park\u00a0H, Yoon\u00a0D, Park\u00a0S, Joung\u00a0B, Park\u00a0RW. Olmesartan is not associated with the risk of enteropathy: a\u00a0Korean nationwide observational cohort study. Korean J Intern Med. 2019;34(1):90-98. \n                    https:\/\/doi.org\/10.3904\/kjim.2017.002","journal-title":"Korean J Intern Med"},{"key":"1539_CR23","doi-asserted-by":"publisher","first-page":"G3","DOI":"10.1152\/ajpcell.1985.249.1.C3","volume":"249","author":"NR Levens","year":"1985","unstructured":"Levens\u00a0NR. Control of intestinal absorption by the renin-angiotensin system. Am J Physiol. 1985;249:G3\u201315.","journal-title":"Am J Physiol"},{"key":"1539_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1748-1716.2010.02165.x","volume":"201","author":"L Fandriks","year":"2011","unstructured":"Fandriks\u00a0L. The renin-angiotensin system and the gastrointestinal mucosa. Acta Physiol (oxf). 2011;201:157\u201367.","journal-title":"Acta Physiol (oxf)"},{"key":"1539_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1470320309347788","volume":"11","author":"L Fandriks","year":"2010","unstructured":"Fandriks\u00a0L. The angiotensin II type 2 receptor and the gastrointestinal tract. J\u00a0Renin Angiotensin Aldosterone Syst. 2010;11:43\u20138.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"1539_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1470320310379066","volume":"12","author":"P Hallersund","year":"2011","unstructured":"Hallersund\u00a0P, Elfvin\u00a0A, Helander\u00a0HF, Fandriks\u00a0L. The expression of renin-angiotensin system components in the human gastric mucosa. J\u00a0Renin Angiotensin Aldosterone Syst. 2011;12:54\u201364.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"1539_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-230X-10-3","volume":"10","author":"P Hallersund","year":"2010","unstructured":"Hallersund\u00a0P, Helander\u00a0HF, Casselbrant\u00a0A, Edebo\u00a0A, Fandriks\u00a0L, Elfvin\u00a0A. Angiotensin II receptor expression and relation to Helicobacter pylori-infection in the stomach of the Mongolian gerbil. Bmc Gastroenterol. 2010;10:3.","journal-title":"Bmc Gastroenterol"},{"key":"1539_CR28","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/apt.13413","volume":"42","author":"EV Marietta","year":"2015","unstructured":"Marietta\u00a0EV, Nadeau\u00a0AM, Cartee\u00a0AK, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015;42:1303\u201314.","journal-title":"Aliment Pharmacol Ther"},{"key":"1539_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.dld.2015.09.014","volume":"48","author":"M Esteve","year":"2016","unstructured":"Esteve\u00a0M, Temino\u00a0R, Carrasco\u00a0A, et al. Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: a population-based study. Dig Liver Dis. 2016;48:154\u201361.","journal-title":"Dig Liver Dis"},{"key":"1539_CR30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/08998280.2017.11929644","volume":"30","author":"VS Ebrahim","year":"2017","unstructured":"Ebrahim\u00a0VS, Martin\u00a0J, Murthy\u00a0S, Odstrcil\u00a0E, Huang\u00a0H, Polter\u00a0D. Olmesartan-associated enteropathy. Proc (bayl Univ Med Cent). 2017;30:348\u201350.","journal-title":"Proc (bayl Univ Med Cent)"},{"key":"1539_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.humpath.2015.12.001","volume":"50","author":"N Burbure","year":"2016","unstructured":"Burbure\u00a0N, Lebwohl\u00a0B, Arguelles-Grande\u00a0C, Green\u00a0PH, Bhagat\u00a0G, Lagana\u00a0S. Olmesartan-associated sprue-like enteropathy: a\u00a0systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127\u201334.","journal-title":"Hum Pathol"},{"key":"1539_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.bbrc.2012.07.003","volume":"424","author":"L Sun","year":"2012","unstructured":"Sun\u00a0L, Wang\u00a0W, Xiao\u00a0W, Liang\u00a0H, Yang\u00a0Y, Yang\u00a0H. Angiotensin II induces apoptosis in intestinal epithelial cells through the AT2 receptor, GATA\u20116 and the Bax pathway. Biochem Biophys Res Commun. 2012;424:663\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1539_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/ccr3.925","volume":"5","author":"S Palmquist","year":"2017","unstructured":"Palmquist\u00a0S, Mathews\u00a0B. Isolated intestinal type angioedema due to ACE-inhibitor therapy. Clin Case Rep. 2017;5:707\u201310.","journal-title":"Clin Case Rep"},{"key":"1539_CR34","first-page":"391","volume":"11","author":"EJ Locascio","year":"2010","unstructured":"Locascio\u00a0EJ, Mahler\u00a0SA, Arnold\u00a0TC. Intestinal angioedema misdiagnosed as recurrent episodes of gastroenteritis. West J Emerg Med. 2010;11:391\u20134.","journal-title":"West J Emerg Med"},{"key":"1539_CR35","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.mayocp.2012.09.011","volume":"87","author":"GH Talbot","year":"2012","unstructured":"Talbot\u00a0GH. Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan. Mayo Clin Proc. 2012;87:1231\u20132. author reply 2.","journal-title":"Mayo Clin Proc"},{"key":"1539_CR36","first-page":"988","volume":"155","author":"AK Cartee","year":"2018","unstructured":"Cartee\u00a0AK, Genere\u00a0RJP, Oxentenko\u00a0AS. New onset villous atrophy in a\u00a0patient with celiac disease. Baillieres Clin Gastroenterol. 2018;155:988\u20139.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"1539_CR37","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.mayocp.2012.10.005","volume":"87","author":"J Menne","year":"2012","unstructured":"Menne\u00a0J, Haller\u00a0H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc. 2012;87:1230\u20131. author reply 2.","journal-title":"Mayo Clin Proc"},{"key":"1539_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.dld.2013.12.014","volume":"46","author":"H Theophile","year":"2014","unstructured":"Theophile\u00a0H, David\u00a0XR, Miremont-Salame\u00a0G, Haramburu\u00a0F. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis. 2014;46:465\u20139.","journal-title":"Dig Liver Dis"},{"key":"1539_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jpge.2015.09.005","volume":"23","author":"M Eusebio","year":"2016","unstructured":"Eusebio\u00a0M, Caldeira\u00a0P, Antunes\u00a0AG, et al. Olmesartan-induced Enteropathy: an unusual cause of villous atrophy. Ge Portuguese J Gastroenterol. 2016;23:91\u20135.","journal-title":"Ge Portuguese J Gastroenterol"},{"key":"1539_CR40","first-page":"1","volume":"0","author":"M Basson","year":"2015","unstructured":"Basson\u00a0M, et\u00a0al. Gut. 2015;0:1\u20136.","journal-title":"Gut"},{"key":"1539_CR41","unstructured":"Ripellino\u00a0C, Cataldo\u00a0N, Scarpignato\u00a0C. Unspecified intestinal malabsortion associated with angiotensin receptor blocker therapy (Abstract). Quintiles IMS, 2016, \n                    https:\/\/www.rwebibliography.com\/print.php?&totalRows_Bibliographies=101&conditionid=7"},{"key":"1539_CR42","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.mayocp.2015.04.002","volume":"90","author":"K Marild","year":"2015","unstructured":"Marild\u00a0K, Lebwohl\u00a0B, Green\u00a0PH, Murray\u00a0JA, Ludvigsson\u00a0JF. Blockers of Angiotensin other than Olmesartan in patients with villous atrophy: a nationwide case-control study. Mayo Clin Proc. 2015;90:730\u20137.","journal-title":"Mayo Clin Proc"},{"key":"1539_CR43","first-page":"67","volume":"30","author":"L Mondet","year":"2016","unstructured":"Mondet\u00a0L, Pierson-Marchandise, Gras\u00a0V, Sevester\u00a0H, Lawson\u00a0P, Andrejak\u00a0M, Masmoudi\u00a0K. Angiotensin\u00a0II receptor blcokers-induced enteropathy: not just olmesartan! A\u00a0case report with candesartan. Fund Clin Pharmacol. 2016;30:67","journal-title":"Fund Clin Pharmacol"},{"key":"1539_CR44","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1177\/1060028016665862","volume":"50","author":"G Famularo","year":"2016","unstructured":"Famularo\u00a0G, Minisola\u00a0G. Relapsing Olmesartan-Associated Ileitis. Ann Pharmacother. 2016;50:1070.","journal-title":"Ann Pharmacother"},{"key":"1539_CR45","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/ajg.2017.281","volume":"112","author":"T van Gils","year":"2017","unstructured":"van Gils\u00a0T, Robijn\u00a0RJ, Bouma\u00a0G, Neefjes-Borst\u00a0EA, Mulder\u00a0CJJ. A pitfall in suspected (refractory) celiac disease: Losartan-induced Enteropathy. Am J Gastroenterol. 2017;112:1754\u20135.","journal-title":"Am J Gastroenterol"},{"key":"1539_CR46","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.14740\/jocmr3047w","volume":"9","author":"A Negro","year":"2017","unstructured":"Negro\u00a0A, De Marco\u00a0L, Cesario\u00a0V, Santi\u00a0R, Boni\u00a0MC, Zanelli\u00a0M. A case of moderate Sprue-like Enteropathy associated with Telmisartan. J\u00a0Clin Med Res. 2017;9:1022\u20135.","journal-title":"J Clin Med Res"},{"key":"1539_CR47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/apt.14176","volume":"46","author":"M Zanelli","year":"2017","unstructured":"Zanelli\u00a0M, Negro\u00a0A, Santi\u00a0R, et al. Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan. Aliment Pharmacol Ther. 2017;46:471\u20133.","journal-title":"Aliment Pharmacol Ther"},{"key":"1539_CR48","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/apt.14518","volume":"47","author":"YH Dong","year":"2018","unstructured":"Dong\u00a0YH, Jin\u00a0Y, Tsacogianis\u00a0TN, He\u00a0M, Hsieh\u00a0PH, Gagne\u00a0JJ. Use of olmesartan and enteropathy outcomes: a\u00a0multi-database study. Aliment Pharmacol Ther. 2018;47:792\u2013800.","journal-title":"Aliment Pharmacol Ther"},{"key":"1539_CR49","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.mayocp.2014.05.012","volume":"89","author":"R Greywoode","year":"2014","unstructured":"Greywoode\u00a0R, Braunstein\u00a0ED, Arguelles-Grande\u00a0C, Green\u00a0PH, Lebwohl\u00a0B. Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a\u00a0case-control study. Mayo Clin Proc. 2014;89:1239\u201343.","journal-title":"Mayo Clin Proc"},{"key":"1539_CR50","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/gastro\/goz019","volume":"7","author":"A Kamal","year":"2019","unstructured":"Kamal\u00a0A, Fain\u00a0C, Park\u00a0A, et al. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a\u00a0systematic review. Gastroenterol Rep (oxf). 2019;7:162\u20137.","journal-title":"Gastroenterol Rep (oxf)"},{"key":"1539_CR51","first-page":"47","volume":"30","author":"I Mondet","year":"2016","unstructured":"Mondet\u00a0I, Pierson-Marchandise\u00a0M, Gras\u00a0V, H.\u00a0S, Lawsan\u00a0P. Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! Fundam Clin Pharmacol. 2016;30:47\u201362.","journal-title":"Fundam Clin Pharmacol"},{"key":"1539_CR52","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","volume":"337","author":"PJ Easterbrook","year":"1991","unstructured":"Easterbrook\u00a0PJ, Berlin\u00a0JA, Gopalan\u00a0R, Matthews\u00a0DR. Publication bias in clinical research. Lancet. 1991;337:867\u201372.","journal-title":"Lancet"},{"key":"1539_CR53","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2018","unstructured":"Ng\u00a0SC, Shi\u00a0HY, Hamidi\u00a0N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a\u00a0systematic review of population-based studies. Lancet. 2018;390:2769\u201378.","journal-title":"Lancet"},{"key":"1539_CR54","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1161\/01.RES.0000258855.60637.58","volume":"100","author":"I Bogdarina","year":"2007","unstructured":"Bogdarina\u00a0I, Welham\u00a0S, King\u00a0PJ, Burns\u00a0SP, Clark\u00a0AJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res. 2007;100:520\u20136.","journal-title":"Circ Res"},{"issue":"Suppl 1","key":"1539_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1710-1492-7-S1-S1","volume":"7","author":"R Warrington","year":"2011","unstructured":"Warrington\u00a0R, Watson\u00a0W, Kim\u00a0HL, Antonetti\u00a0FR. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):1.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1539_CR56","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/j.1440-1746.2009.05932.x","volume":"24","author":"AG Cummins","year":"2009","unstructured":"Cummins\u00a0AG, Roberts-Thomson\u00a0IC. Prevalence of celiac disease in the Asia-Pacific region. J\u00a0Gastroenterol Hepatol. 2009;24:1347\u201351.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-01539-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-019-01539-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-01539-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T23:51:26Z","timestamp":1598658686000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-019-01539-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":56,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1539"],"URL":"https:\/\/doi.org\/10.1007\/s00508-019-01539-2","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]},"assertion":[{"value":"16 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.R.\u00a0Wenzel: For the following companies there is a conflict of interest with the presented data due to consultancy fees or sponsoring: Actelion, Astra-Zeneca, Abbott, Bayer, Daichii-Sankyo, Gepamed, Medtronic, Menarini, Novartis, Speedel Pharma, St Jude Medical and Takeda. C.\u00a0Datz declares that he has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}